你这家伙还行不行？？_老虎社区_美港股上老虎

你这家伙还行不行？？？

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":442816820503304,"tweetId":"442816820503304","gmtCreate":1749131958333,"gmtModify":1749131959857,"author":{"id":3576724815704857,"idStr":"3576724815704857","authorId":3576724815704857,"authorIdStr":"3576724815704857","name":"去会所","avatar":"https://static.tigerbbs.com/de401c0bd93eac5813aa71ee994e439c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>你这家伙还行不行？？？</p></body></html>","htmlText":"<html><head></head><body><p>你这家伙还行不行？？？</p></body></html>","text":"你这家伙还行不行？？？","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/442816820503304","repostId":2541440017,"repostType":2,"repost":{"id":"2541440017","kind":"news","pubTimestamp":1749096678,"share":"https://www.laohu8.com/m/news/2541440017?lang=&edition=full","pubTime":"2025-06-05 12:11","market":"us","language":"zh","title":"再生元制药公司6月4日成交额为9.18亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541440017","media":"市场透视","summary":"美东时间2025年6月4日，再生元制药公司成交额为9.18亿美元，成交额较昨日减少12.75%，当日成交量为187.07万股。再生元制药公司于2025年6月4日跌0.6%，报484.93美元，该股过去5个交易日跌18.07%，年初至今跌31.73%，过去60日跌34.8%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","content":"<html><body><article><p>美东时间2025年6月4日，<a href=\"https://laohu8.com/S/REGN\">再生元制药公司</a>（REGN.US）成交额为9.18亿美元，成交额较昨日减少12.75%，当日成交量为187.07万股。</p><p>再生元制药公司（REGN.US）于2025年6月4日跌0.6%，报484.93美元，该股过去5个交易日跌18.07%，年初至今跌31.73%，过去60日跌34.8%。</p><p>|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-04|9.18亿|-12.75%|187.07万|#|2025-06-03|10.52亿|-27.32%|214.16万|#|2025-06-02|14.48亿|-53.61%|294.43万|#|2025-05-30|31.21亿|585.07%|631.31万|#|2025-05-29|4.56亿|-24.30%|75.68万|</p><p>Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。Regeneron还与<a href=\"https://laohu8.com/S/0O59.UK\">赛诺菲</a>以及其他合作伙伴合作开发单克隆和双特异性抗体，并建立了早期合作伙伴关系，为产品线带来新技术，其中包括 RNAi（Alnylam）和基于 Crispr 的基因编辑（Intellia）。</p><p>（以上内容为<a href=\"https://laohu8.com/S/00700\">腾讯</a>自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再生元制药公司6月4日成交额为9.18亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再生元制药公司6月4日成交额为9.18亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-05 12:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605121123a49ace13&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美东时间2025年6月4日，再生元制药公司（REGN.US）成交额为9.18亿美元，成交额较昨日减少12.75%，当日成交量为187.07万股。再生元制药公司（REGN.US）于2025年6月4日跌0.6%，报484.93美元，该股过去5个交易日跌18.07%，年初至今跌31.73%，过去60日跌34.8%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605121123a49ace13&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4585":"ETF&股票定投概念","REGN":"再生元制药公司","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4139":"生物科技","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4588":"碎股","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605121123a49ace13&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2541440017","content_text":"美东时间2025年6月4日，再生元制药公司（REGN.US）成交额为9.18亿美元，成交额较昨日减少12.75%，当日成交量为187.07万股。再生元制药公司（REGN.US）于2025年6月4日跌0.6%，报484.93美元，该股过去5个交易日跌18.07%，年初至今跌31.73%，过去60日跌34.8%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-04|9.18亿|-12.75%|187.07万|#|2025-06-03|10.52亿|-27.32%|214.16万|#|2025-06-02|14.48亿|-53.61%|294.43万|#|2025-05-30|31.21亿|585.07%|631.31万|#|2025-05-29|4.56亿|-24.30%|75.68万|Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。Regeneron还与赛诺菲以及其他合作伙伴合作开发单克隆和双特异性抗体，并建立了早期合作伙伴关系，为产品线带来新技术，其中包括 RNAi（Alnylam）和基于 Crispr 的基因编辑（Intellia）。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","news_type":1,"symbols_score_info":{"REGN":1}},"isVote":1,"tweetType":1,"viewCount":289,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/442816820503304"}